NCT03524339View on ClinicalTrials.gov

Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

June 9, 2020

Study Completion Date

June 9, 2020

Conditions
Urinary RetentionLower Urinary Tract SymptomsStress Urinary IncontinencePelvic Organ Prolapse
Interventions
DRUG

Placebo oral capsule

Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.

DRUG

Tamsulosin

Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.

Trial Locations (2)

44106

University Hospitals Cleveland Medical Center, Cleveland

University Hospitals, Cleveland

All Listed Sponsors
lead

University Hospitals Cleveland Medical Center

OTHER

NCT03524339 - Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery | Biotech Hunter | Biotech Hunter